Welcome to the e-CCO Library!

P616: Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Focht, G.(1)*;Turner, S.(2);Carmon, N.(1);Lev-Tzion, R.(1);Orlanski-Meyer, E.(1);Ledder, O.(1);Yogev, D.(1);Assa, A.(3);Turner, D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P616: Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tse C.S.*1, Deepak P.2, De La Fuente J.1, Murray J.2, Papadakis K.2

Created: Wednesday, 20 February 2019, 10:36 AM
P616: Safety of COVID-19 vaccines in patients with IBD
Year: 2022
Source: ECCO'22
Authors: Dussias, N.(1);Carbone, A.(1);Melotti, L.(1);Privitera Hrustemovic, H.(1);Salice, M.(1);Scaioli, E.(1);Calabrese, C.(1);Rizzello, F.(1);Gionchetti, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P616: Sustainability of thiopurines monotherapy in ulcerative colitis: a nationwide analysis from the epi-IIRN cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Friss, C.(1); Mendelovici, A.(1); Shteyer, E.(1); Orlanski-Meyer, E.(1); Ledderman, N.(2); Greenfeld, S.(3); Kariv, R.(3); Loewenberg Weisband, Y.(4);Gabay, H.(5); Nevo, D.(6); Matz, E.(7); Dotan, I.(8);Turner, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P616: Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Rao*1, R. Gadhok1, L. Whitley2, N. Burgess1, P. Amon1, S. Naik1, J. Lindsay1, S. McCartney2, K. Kok1

Created: Friday, 22 February 2019, 9:41 AM
P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Leventi1,2, A. Aksan2,3*, J. Stein1,2, K. Farrag1,2

Created: Thursday, 21 February 2019, 9:14 AM
P617 Mesenchymal stromal cells of bone marrow reduce the risk of postoperative recurrence of Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Knyazev, A.V. Kagramanova, A. Lishchinskaya, A. Parfenov

Created: Thursday, 30 January 2020, 10:12 AM
P617: Dual biologic therapy in pediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abbas, R.(1)*;Ibrahim, N.(1);Elawad, M.(1);Al-Mudahka, F.(1);Abdelrhman, H.(1);K.Akobeng, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P617: Evaluation of subclinical myocardial damage in patients with inflammatory bowel disease on treatment with biologics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Costantino*1, G. Mandraffino1, S. Tomeo1, A. Sitibondo1, M. Scolaro1, C. Zito2, G. Di Bella2, S. Loddo3, W. Fries1

Created: Friday, 22 February 2019, 9:41 AM
P617: Extraintestinal autoimmune phenomena during treatment with vedolizumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lissner D.*1, Sonnenberg E.1, Glauben R.1, Allers C.1, Preiss J.1, Schneider T.1, Loddenkemper C.2, Siegmund B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Daferera1*, S. Ignatova2, A. Münch3

Created: Thursday, 21 February 2019, 9:14 AM
P617: Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital.
Year: 2022
Source: ECCO'22
Authors: Chivato Martín Falquina , I.(1);Saiz Chumillas , R.M.(1);Arias Garcia , L.(1);Vicente González , B.(2);Revilla Cuesta , N.(2);Alba Hernández , L.(1);Andrés Pascual , L.(1);Sicilia Aladrén , B.(1);
Created: Friday, 11 February 2022, 3:56 PM
P617: Trends in Pediatric Inflammatory Bowel Disease-attributable direct costs: A Canadian population-based analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: El-Matary, W.(1);Nugent, Z.(2);Witt, J.(3);Bernstein, C.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P618 Post-operative Crohn’s disease patients undergoing colonoscopy require significantly more analgesia and sedation compared with a non-IBD population
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Rowan1, M. Janjua1, C. Foley1, J. Burke2, K. Boland1, A. O’Toole1

Created: Thursday, 30 January 2020, 10:12 AM
P618: Long-term real-world data of Ustekinumab in Ulcerative Colitis – the Stockholm Ustekinumab study – STOCUSTE
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sabhan, H.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P618: Post-operative pain following laparoscopic right hemicolectomy for Crohn’s disease a comparative study
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. McKevitt*, S. Galvin, J. Burke

Created: Thursday, 21 February 2019, 9:14 AM
P618: Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort study
Year: 2022
Source: ECCO'22
Authors: Meade, S.(1);Patel, K.V.(2);Luber, R.P.(3);O’Hanlon, D.(4);Caracostea, A.(1);Pavlidis, P.(5);Honap, S.(1);Anandarajah, C.(1);Griffin, N.(6);Zeki, S.(1);Ray, S.(1);Mawdsley, J.(1);Samaan , M.A.(1);Anderson, S.H.(1);Darakhshan, A.(7);Adams, K.(7);Williams, A.(7);Sanderson, J.D.(1);Lomer, M.(4);Irving, P.M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P618: Rapidity of onset of response to adalimumab in luminal Crohn's disease. Data from RAPIDA trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Marin-Jimenez I.*1, Casellas F.2, Esteve M.3, Castro-Laria L.4, García-Lόpez S.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Vicente R.5, Rodriguez-San Pedro L.13, Diaz G.14, Casado R.14, Barreiro-de Acosta M.15

Created: Wednesday, 20 February 2019, 10:36 AM
P618: Treatment outcomes of patients with Crohn’s disease and complex perianal fistula in five European countries: the PREFACE retrospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferrante, M.(1);Siproudhis, L.(2);Poggioli, G.(3);Reinshagen, M.(4);Milicevic, S.(5);Roset, M.(6);Bent-Ennakhi, N.(5);D‘Ambrosio, R.(5);Fernandez-Nistal, A.(7);Panes, J.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P618: Vedolizumab acute infusion reactions in inflammatory bowel disease patients: results of a multi-centre retrospective observational cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Venturin1, S. Nancey1, X. Roblin2, L. Peyrin-Biroulet3, N. Mathieu4, B. Flourié1, G. Boschetti*1

Created: Friday, 22 February 2019, 9:41 AM